Neuromuscular Effects of Sevoflurane in a Patient with Myasthenia Gravis
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Anaesthetic management of myasthenia gravis in coronary artery bypass grafting.
Vanjari V, Maybauer M Ann Card Anaesth. 2020; 23(2):209-211.
PMID: 32275037 PMC: 7336980. DOI: 10.4103/aca.ACA_176_18.
Ballal M, Straker T Case Rep Med. 2015; 2015:593586.
PMID: 26294914 PMC: 4532903. DOI: 10.1155/2015/593586.
References
1.
Seybold M
. Myasthenia gravis. A clinical and basic science review. JAMA. 1983; 250(18):2516-21.
DOI: 10.1001/jama.250.18.2516.
View
2.
Itagaki T, Tai K, Katsumata N, Suzuki H
. [A clinical and experimental study on potentiation with sevoflurane of neuromuscular blocking effects of vecuronium and pancuronium]. Masui. 1988; 37(8):943-54.
View
3.
Blitt C, WRIGHT W, Peat J
. Pancuronium and the patient with myasthenia gravis. Anesthesiology. 1975; 42(5):624-6.
DOI: 10.1097/00000542-197505000-00027.
View
4.
Holaday D, Smith F
. Clinical characteristics and biotransformation of sevoflurane in healthy human volunteers. Anesthesiology. 1981; 54(2):100-6.
DOI: 10.1097/00000542-198102000-00002.
View
5.
Nilsson E, Paloheimo M, Muller K, Heinonen J
. Halothane-induced variability in the neuromuscular transmission of patients with myasthenia gravis. Acta Anaesthesiol Scand. 1989; 33(5):395-401.
DOI: 10.1111/j.1399-6576.1989.tb02931.x.
View